

Published in final edited form as:

*Muscle Nerve*. 2011 August ; 44(2): 174–178. doi:10.1002/mus.22047.

## CINRG Pilot trial of Coenzyme Q10 in steroid treated Duchenne Muscular Dystrophy

Christopher F. Spurney, MD<sup>1</sup>, Carolina Tesi Rocha, MD<sup>1</sup>, Erik Henricson, MPH<sup>1</sup>, Julaine Florence, DPT<sup>2</sup>, Jill Mayhew, PT<sup>3</sup>, Ksenija Gorni, MD<sup>1</sup>, Livia Pasquali, MD<sup>1</sup>, Alan Pestronk, MD<sup>2</sup>, Gerard R. Martin, MD<sup>1</sup>, Fengming Hu, PhD<sup>1</sup>, Lei Nie, PhD<sup>4</sup>, Anne M. Connolly, MD<sup>2</sup>, Diana M. Escolar, MD<sup>1</sup>, and CINRG investigators\*

<sup>1</sup> Children's National Medical Center, George Washington University, Washington DC

<sup>2</sup> Washington University, St. Louis MO

<sup>3</sup> Children's Hospital, Richmond VA

<sup>4</sup> Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington DC

### Abstract

**Introduction**—Corticosteroid treatment slows disease progression and is the standard of care for Duchenne muscular dystrophy (DMD). Coenzyme Q10 (CoQ10) is a potent antioxidant that may improve function in dystrophin deficient muscle.

**Methods**—We performed an open label, “add-on” pilot study of CoQ10 in thirteen 5–10 year old DMD patients on steroids. The primary outcome measure was the total Quantitative Muscle Testing (QMT) score.

**Results**—Twelve of 16 children (mean age 8.03±1.64 years) completed the trial. Target serum levels of CoQ10 (≥2.5 µg/ml) were shown to be subject- and administration-dependent. Nine of 12 subjects showed an increase in total QMT score. Overall, CoQ10 treatment resulted in 8.5 % increase in muscle strength (p=0.03).

**Discussion**—This pilot study found the addition of CoQ10 to prednisone therapy in DMD patients resulted in an increase in muscle strength. These results warrant a larger, controlled trial of CoQ10 in DMD.

### Keywords

Duchenne muscular dystrophy; CoQ10; steroids; muscle strength testing; clinical trial

### Introduction

Duchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrophy affecting 1 in 3500 males. Corticosteroids are the standard of care and slow

---

Corresponding author: Diana M. Escolar, MD, Associate Professor of Neurology, Johns Hopkins Medical School, Center for Genetic Muscle Disorders, Kennedy Krieger Institute, 801 North Broadway, Baltimore, MD, Mailing address and contact information: 1528 Poplar PL, McLean, VA 22101, Phone: 703-927-6469, diana.escolar@gmail.com.

\*CINRG participating investigators

Children's National Medical Center- Washington, DC: Escolar, D; Henricson, E; Bartczak, M; Parker, K; McCarter, R; Morton, L; Jilles, C; Washington University, St. Louis – St. Louis, MO: Connolly, A; Pestronk, A; Wulf, C; Florence, J; Schierbecker, J; Renna, R

Presented as an oral presentation at the 2007 AAN annual meeting

muscle disease progression.<sup>1</sup> However, it is likely that a “cocktail” of drugs that target important pathophysiological pathways in DMD (inflammation, metabolic insufficiency, fibrosis, apoptosis, and others) could synergistically provide better disease control than steroids alone.<sup>2</sup> This approach was validated in the dystrophin-deficient mdx mouse model.<sup>1,3</sup>

One potential additional therapy in DMD is Coenzyme Q10 (CoQ10). CoQ10 is a hydrophobic molecule bound to the inner mitochondrial membrane that functions as an electron acceptor molecule for complexes I (NADH) and II (SDH) of the respiratory chain. Exogenous incorporation of CoQ10 into mitochondria can double the oxidative activity of NADH, thus providing metabolic support to muscle.<sup>4</sup> CoQ10 is also a potent antioxidant which is able to reduce the excessive oxidative radicals and calcium overload in DMD muscles.<sup>5,6</sup> In addition, CoQ10 modulates the mitochondrial transition pore and could decrease mitochondrial calcium accumulation.<sup>7</sup> Pre-clinical studies in exercised mdx mice showed that CoQ10 treatment preserved strength by 42% compared to controls (Personal communication, Granchelli 2000).<sup>8</sup>

We conducted this pilot trial to determine whether the addition of CoQ10 to a stable steroid regimen could further preserve or increase muscle strength in DMD. A secondary objective was to find an effective and safe dose of CoQ10 in this pediatric population.

## Material and Methods

### Trial Design

We conducted a prospective, open label pilot study of oral CoQ10 supplementation (Myoquinon Q10 30 and 100 mg tablets, PharmaNord, ApS, IND #62,369) in ambulant DMD children between 5 and 10 years of age with an established DMD diagnosis on a stable regimen of prednisone for more than 6 months. Each child served as his own control. Exclusion criteria included severe systemic diseases, recent or current use of CoQ10, glutamine, creatine or other herbal supplements.

Participants were recruited from two centers (Children’s National Medical Center, Washington DC and Washington University, St. Louis MO), with institutional review board approval at each site in accordance with the Helsinki Declaration. After obtaining assent from participants and consent from their parents, participants underwent two screening evaluations. Those able to repeat elbow flexion Quantitative Muscle Testing (QMT) within 15% of their initial performance were enrolled in the study. This inclusion criterion assures that patients enrolled in the study can reliably perform the required testing.<sup>9,10</sup>

### Dose optimization

Normal serum levels of CoQ10 have been established in adults and pediatric healthy individuals.<sup>11,12</sup> Exogenous supplementation of CoQ10 results in varied elevation of blood levels with those above 2.5 µg/ml being considered therapeutic for several disease states.<sup>11,12</sup> We used a dose-escalation design with HPLC assessment of serum CoQ10 levels with a 2.5 µg/ml target.

Participants underwent 3 months of lead-in evaluation at their pre-established dose of prednisone, and then began a CoQ10 dose-finding period at a starting dose of 90 mg CoQ10 daily and a dose escalation of 30 mg daily until achieving a serum CoQ10 level of 2.5 µg/ml. With the initial 3 patients we were unable to rapidly achieve desired levels so we modified the protocol to increase the initial dose to 400 mg with dose escalations of 100 mg. In addition, the drug was given with a small fatty snack (ice cream). Once the minimum level was achieved, participants began the 6 month evaluation period, with repeat drug level

monitoring at each visit. Dose adjustments were performed as needed, and reductions were only performed if there were side effects considered to be related to the drug. We performed pill count and review of medication diaries as a method to monitor for compliance and possible medication interactions.

### Outcome measures

The primary outcome measure was the total Quantitative Muscle Testing (QMT) score.<sup>13,14</sup> Maximal isometric muscle strength, measured by the Richmond Quantitative Measurement System (RQMS) of bilateral elbow and knee flexors and extensors, and grip was performed. A total QMT score was calculated as the mean of the 10 RQMS scores (grip R/L, elbow extension R/L, elbow flexion R/L, knee extension R/L and knee flexion R/L). QMT was chosen due to the need for a highly sensitive and reliable method of strength measurement in this small pilot trial. Secondary outcomes were arm, leg and grip QMT scores, manual muscle testing (MMT) score, timed function tests (time to climb 4 steps, to stand up from a supine position on the floor and to walk/run 10 meters), left ventricular ejection fraction as measured by 2D-echocardiography (Phillips Sonos 5500) and electrocardiograms.<sup>15,13</sup> Safety evaluations included clinical and laboratory monitoring for cell blood count, basic chemistries and liver function tests.

### Statistical considerations

Total QMT score and secondary outcomes were measured at baseline, end of lead-in period and monthly thereafter during the 6 months of treatment (T1 to T6). Data were analyzed using paired t-tests (two-sided) on the changes in scores and timed measurements between the end of the treatment cycle and lead-in. P values less than or equal to 0.05 were considered statistically significant. Missing data at Lead-In 3 and Treatment Month 6 were replaced by using the last observations carried forward for the QMT muscle scores. This imputation was done for 6 patients. The data in log scale were also analyzed using paired t-tests as references. Linear mixed-effects models were used to investigate the linear trend in the total QMT scores.<sup>16,17</sup>

### Results

Sixteen children were screened. Three children did not meet the QMT reliability inclusion criterion. Thirteen children 5 to 10 years old, mean age  $8.03 \pm 1.64$ , were enrolled in the lead-in phase, but one obese child was removed from the study due to failure to achieve target CoQ10 levels despite several months of dose escalation to up to 800 mg/day. Twelve participants completed the trial.

Table 1 gives the average values of the primary and secondary outcome measures at baseline, end of lead-in period, and end of month 6 for all subjects completing the study. There was a significant ( $p=0.03$ ) increase in the average total QMT score from TI3 to the end of treatment (from 11.7 to 12.7 lbs or 8.5%). Analysis of individual QMT scores changes shows an average 1.01 lbs increase in the QMT score from LI3 to Month 6 with a standard error of 1.4 lbs. This was reproduced with the analysis in log scale ( $p=0.046$ ).

Figure 1 shows the observed and fitted values of the total QMT score throughout the treatment period. The total QMT score increased by 0.06 lbs/month during the treatment period (slope  $p=0.28$ ). This trend supports the beneficial effect of CoQ10 on muscle strength.

Among all 12 subjects who completed the study, nine subjects (age 5.2 to 10.2 years) showed an increase in total QMT score from baseline. Among them, six subjects showed at least a 10% increase in QMT total scores; one subject increased 8%, one increased 6%, and

one increased 2% in QMT total score (Figure 2). The 3 patients who did not show an improvement were between 7.5 to 8.7 years old. The percent increase results are generally consistent within the QMT arm (11%), leg (8%) and hand grip (9%) scores. Correlation analysis showed that there was no significant correlation between the individual response and baseline disease severity in total QMT or any other strength parameters. In addition, the spread of the age of the patients who showed some improvement included only 2 children under the age of 7. This suggests that the effect measured was not due to a “honeymoon” period.

There were no significant changes in cardiac parameters during the trial. At the start of the trial, the ejection fraction ( $62\pm4\%$ ), left ventricular internal diameter ( $3.8\pm0.2$  cm) and posterior wall thickness ( $0.6\pm0.1$  cm) during diastole and electrocardiograms were normal and did not change significantly at the end of the trial.

There was no correlation between baseline CoQ10 serum levels and disease severity as measured by the baseline total QMT score. There were also no significant correlations between age at baseline or disease severity and response to CoQ10 treatment.

There was significant variability between subjects in achieving target serum concentrations of CoQ10. To achieve the same level, children required doses ranging between 90 and 510 mg per day. The average dose/kg weight at the end of the study was 27.8 mg/kg ranging from 8.7 to 48.4 mg/kg. Initial CoQ10 serum levels varied between 0.6 to 3.6  $\mu\text{g/ml}$ , when the initial dose was 90 mg, and 1.3 to 8.1  $\mu\text{g/ml}$ , when the initial dose was changed to 400 mg. Serum levels increased more rapidly and remained more constant when CoQ10 was co-delivered with a small fatty snack, presumably due to increased bioavailability of the CoQ10. Serum levels were maintained between 2.6 and 9.2  $\mu\text{g/ml}$  during the 6-month treatment phase for all subjects. There was no correlation between baseline total QMT score and dose required to maintain the therapeutic level.

There were no serious adverse events. One patient developed a headache of moderate intensity associated with high blood levels of CoQ10 (7.37  $\mu\text{g/ml}$ , dose 400 mg, 20 mg/kg). The event resolved with a decrease of the dose to 200 mg per day (serum level 3.66  $\mu\text{g/ml}$ ).

## Discussion

This limited study shows the addition of CoQ10 to prednisone treatment in DMD results in an average improvement of QMT total score of 1.0 lbs (8.5%) from LI3 ( $p=0.03$ ), above and beyond steroid-related improvements. Secondary outcomes, including MMT score, and individual QMT scores all showed improvements. These results suggest that further testing of CoQ10 as an additional therapy in DMD is warranted.

Two previous studies have shown the efficacy of CoQ10 in dystrophinopathies, although quantitative muscle strength was not an outcome measure in either study.<sup>6,18,19</sup> QMT is a very sensitive measure of strength, however the clinical significance of an 8.5% increase in total score is not yet established. In this study, this magnitude of increase in muscle strength did not relate to an improvement in function. In a DMD prednisone study recently completed by the Cooperative International Neuromuscular Research Group (CINRG), obvious clinical and functional benefits were seen when the QMT total score improved by 15% (publication in process). A more important point is that there was no further decrease in muscle scores. The participants' average age was almost 9 years old and they were absolutely outside a honeymoon period and in the deterioration state of the disease, even on prednisone. A recent study of ours found that children aged 7 and older show deterioration in QMT scores (unpublished data). So, even stabilization of QMT scores during this 6 month trial could be a beneficial effect of CoQ10. A longer trial duration and larger sample

size could help evaluate the effects of this magnitude of strength improvement on function and other less sensitive strength measurements (MMT).

CoQ10 treatment for 6 months was well tolerated in this patient cohort. There was significant variability in the dose required to achieve therapeutic blood levels. From this study, we suggest that the starting dose of CoQ10 should be 400 mg per day, and it should be increased by 100 mg per day according to serum levels. The 400 mg dose was well tolerated and led to rapid therapeutic levels in most participants. Of importance, we note that CoQ10 absorption was improved when it was administered with a small fatty snack, usually ice cream. Future administrations of CoQ10 should consider this or a similar method to minimize dosing and optimize serum levels.

We were unable to obtain therapeutic serum levels in one obese child. While the specific reason for this is not known, cholesterol levels can alter plasma levels of CoQ10.<sup>20</sup> Although we performed clinically relevant biochemical tests during treatment that did not show any abnormalities, cholesterol levels were not part of this study and may have played a role in difficult patients. We would recommend cholesterol levels be included in the chemistry panels of a larger, controlled future study.

Although we monitored cardiac function in this study, there was an absence of cardiac abnormalities in our study population. This was likely related to the age of our population and also the concurrent use of steroids which were shown to preserve cardiac function in a previous study.<sup>21</sup> The effects of CoQ10 on cardiac function in DMD patients still need further investigation.

This study was limited by a small cohort of patients, lack of randomization and short duration of therapy. However, the effect size found in this pilot trial can be used for power analysis in the design of future studies.

In conclusion, this study found an increase in muscle strength in steroid treated DMD patients given CoQ10 for 6 months. The results are encouraging and indicate a potential role for CoQ10 therapy in young DMD patients, and further controlled randomized trials are warranted.

## Acknowledgments

The authors are grateful to: Dr. Giancarlo Littaru of the International CoQ10 Association; PharmaNord for providing the study medication; Deanna DeMott and Angela Zimmerman for their invaluable coordination role within CINRG; Annie Kennedy for her continuous support and interface with participants; all participants and parents that participated in the study; and Paula Clemens, MD for her helpful input on this manuscript.

This work was supported by the Muscular Dystrophy Association, PharmaNord, the GCRC grant M01-RR13297, MO1-RR00084, RR011126 NCRR, and K-23 RR16281-01 from NCRR, NIH.

## Abbreviations in order that appear in the text


<b>DMD</b>	Duchenne Muscular Dystrophy
<b>CoQ10</b>	Coenzyme Q10
<b>NADH</b>	Nicotinamide Adenine Dinucleotide
<b>SDH</b>	Succinyl Dehydrogenase
<b>QMT</b>	Quantitative Muscle Testing
<b>HPLC</b>	High Performance Liquid Chromatography

<b>RQMS</b>	Richmond Quantitative Measurement System
<b>R/L</b>	right/left
<b>MMT</b>	Manual Muscle Testing
<b>2D</b>	two dimensional
<b>CINRG</b>	Cooperative International Neuromuscular Research Group

## References


1. Moxley RT 3rd, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, Baumbach L, McDonald C, Sussman M, Wade C. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology*. 2005; 64(1):13–20. [PubMed: 15642897]
2. Chen YW, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R, Hoffman EP. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. *Neurology*. 2005; 65(6):826–834. [PubMed: 16093456]
3. Payne ET, Yasuda N, Bourgeois JM, Devries MC, Rodriguez MC, Yousuf J, Tarnopolsky MA. Nutritional therapy improves function and complements corticosteroid intervention in mdx mice. *Muscle Nerve*. 2006; 33(1):66–77. [PubMed: 16149047]
4. Lonrot K, Holm P, Lagerstedt A, Huhtala H, Alho H. The effects of lifelong ubiquinone Q10 supplementation on the Q9 and Q10 tissue concentrations and life span of male rats and mice. *Biochem Mol Biol Int*. 1998; 44(4):727–737. [PubMed: 9584986]
5. Okamoto T, Kubota N, Takahata K, Takahashi T, Goshima K, Kishi T. Protective effect of coenzyme Q10 on cultured skeletal muscle cell injury induced by continuous electric field stimulation. *Biochem Biophys Res Commun*. 1995; 216(3):1006–1012. [PubMed: 7488172]
6. Rando TA, Crowley RS, Carlson EJ, Epstein CJ, Mohapatra PK. Overexpression of copper/zinc superoxide dismutase: a novel cause of murine muscular dystrophy. *Ann Neurol*. 1998; 44(3):381–386. [PubMed: 9749606]
7. Papucci L, Schiavone N, Witort E, Donnini M, Lapucci A, Tempestini A, Formigli L, Zecchi-Orlandini S, Orlandini G, Carella G, Brancato R, Capaccioli S. Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. *J Biol Chem*. 2003; 278(30):28220–28228. [PubMed: 12736273]
8. Granchelli JA, Pollina C, Hudecki MS. Pre-clinical screening of drugs using the mdx mouse. *Neuromuscul Disord*. 2000; 10(4–5):235–239. [PubMed: 10838248]
9. Buyse GM, Goemans N, Henricson E, Jara A, van den Hauwe M, Leshner R, Florence JM, Mayhew JE, Escolar DM. CINRG pilot trial of oxatomide in steroid-naïve Duchenne muscular dystrophy. *Eur J Paediatr Neurol*. 2007; 11(6):337–340. [PubMed: 17459739]
10. Escolar DM, Buyse G, Henricson E, Leshner R, Florence J, Mayhew J, Tesi-Rocha C, Gorni K, Pasquali L, Patel KM, McCarter R, Huang J, Mayhew T, Bertorini T, Carlo J, Connolly AM, Clemens PR, Goemans N, Iannaccone ST, Igarashi M, Nevo Y, Pestronk A, Subramony SH, Vedanarayanan VV, Wessel H. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. *Ann Neurol*. 2005; 58(1):151–155. [PubMed: 15984021]
11. Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P. Effective and safe therapy with coenzyme Q10 for cardiomyopathy. *Klin Wochenschr*. 1988; 66(13):583–590. [PubMed: 3062263]
12. Littarru GP, Mosca F, Fattorini D, Bompadre S, Battino M. Assay of coenzyme Q10 in plasma by a single dilution step. *Methods Enzymol*. 2004; 378:170–176. [PubMed: 15038968]
13. Escolar DM, Henricson EK, Mayhew J, Florence J, Leshner R, Patel KM, Clemens PR. Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children. *Muscle Nerve*. 2001; 24(6):787–793. [PubMed: 11360262]

14. Mayhew JE, Florence JM, Mayhew TP, Henricson EK, Leshner RT, McCarter RJ, Escolar DM. Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy. *Muscle Nerve*. 2007; 35(1):36–42. [PubMed: 16969838]
15. Mendell JR, Province MA, Moxley RT 3rd, Griggs RC, Brooke MH, Fenichel GM, Miller JP, Kaiser KK, King W, Robison J, et al. Clinical investigation of Duchenne muscular dystrophy. A methodology for therapeutic trials based on natural history controls. *Arch Neurol*. 1987; 44(8): 808–811. [PubMed: 3115236]
16. Verbeke G, Molenberghs G, Thijs H, Lesaffre E, Kenward MG. Sensitivity analysis for nonrandom dropout: a local influence approach. *Biometrics*. 2001; 57(1):7–14. [PubMed: 11252620]
17. Verbeke G, Molenberghs G. The use of score tests for inference on variance components. *Biometrics*. 2003; 59(2):254–262. [PubMed: 12926710]
18. Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. *Biochim Biophys Acta*. 1995; 1271(1):281–286. [PubMed: 7599221]
19. Folkers K, Wolaniuk J, Simonsen R, Morishita M, Vadhanavikit S. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. *Proc Natl Acad Sci U S A*. 1985; 82(13):4513–4516. [PubMed: 3859873]
20. Kaikkonen J, Tuomainen TP, Nyyssonen K, Salonen JT. Coenzyme Q10: absorption, antioxidative properties, determinants, and plasma levels. *Free Radic Res*. 2002; 36(4):389–397. [PubMed: 12069102]
21. Markham LW, Spicer RL, Khoury PR, Wong BL, Mathews KD, Cripe LH. Steroid therapy and cardiac function in Duchenne muscular dystrophy. *Pediatr Cardiol*. 2005; 26(6):768–771. [PubMed: 15990951]



**Figure 1.**

Plots of mean  $\pm$  standard deviation of the observed data at each of the time points from Lead-In 3 to Treatment Month 6 and fitted trend lines obtained in the trend analysis via mixed-effects models. Lead-In 3 is the period immediately prior to the treatment cycles. Please note the linear trend does not apply to the period from the Lead-In 3 to Treatment Month 1, because the time from the end of Lead-In 3 to the start of Treatment Month 1 varies from patient to patient due to the dose escalation required to reach the desired level.



**Figure 2.** Individual QMT total score (lbs) for 12 patients from Baseline to Treatment Month 6 showing an overall increase in muscle strength of 9 subjects.

**Table 1**

Average values of primary and secondary outcomes at baseline, end of Lead-In period, and Treatment Month 6 showing increases in muscle strength testing with significant improvements seen in QMT total score at Treatment Month 6 compared to Lead-In 3 ( $p=0.03$ ).

Measurements	Baseline Mean(SD)	LI 3 Mean(SD)	TM 6 Mean(SD)	P-values		
				Baseline vs. LI3	LI3 vs. TM 6	Baseline vs. TM 6
QMT total score (lbs)	11.6(2.0)	11.7(1.8)	12.7(2.4)	0.75	0.03	0.06
QMT arm score (lbs)	9.0(2.0)	9.2(2.3)	10.0(2.6)	0.60	0.10	0.09
QMT leg score (lbs)	13.6(2.5)	13.8(2.7)	14.9(3.2)	0.72	0.11	0.11
QMT grip score (lbs)	12.6(3.2)	12.5(1.7)	13.7(2.9)	0.94	0.16	0.16
MMT score	237.4(10.9)	233.8(12.1)	244.5(20.9)	0.49	0.35	0.48
Timed walk (s)	5.3(1.7)	5.3(1.8)	5.8(2.9)	0.58	0.24	0.22
Timed climb 4 steps (s)	4.3(2.9)	4.1(3.0)	4.5(4.3)	0.83	0.43	0.74
Timed standing from lying position (s)	4.3(1.8)	4.2(1.1)	5.7(3.8)	0.68	0.12	0.09

Abbreviations: LI3 – Lead-In 3; MMT – Manual Muscle Testing; QMT – Quantitative Muscle Testing; SD – standard deviation; TM 6 – Treatment Month 6